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Background: Cryoablation is one of the local therapies for hepatocellular carcinoma (HCC), but its safety and effect
has not been studied in patients with Child class A or B and Barcelona Clinic Liver Cancer (BCLC) stage C HCC.
Metastasis-associated in colon cancer-1 (MACC1) overexpression has been associated with poor prognosis of HCC,
but its predictive value to post-cryoablation outcomes remains unknown in patients with BCLC stage C HCC.
Methods: This study assessed the safety and outcomes of cryoablation measured by time to progression (TTP)
and overall survival (OS), and predictive value of MACC1 mRNA and protein overexpression in tumorous tissue
to post-cryoablation outcomes in 120 advanced HCC patients with child-pugh class A or B by quantitative
polymerase chain reaction and immunohistochemical staining. The potenial correlation of MACC1 and c-Met
expression to tumor cell proliferation and apoptosis was also analyzed.
Results: The cryoablation in patients with advanced unresectable HCC resulted in a median TTP and OS of 5.5
(4.2- 6.7) months and 10.5 (9.0-12.0) months, respectively and no significant complications, comparable to the
historical report for RFA therapy. The MACC1 mRNA and nuclear protein expression was significantly increased
in tumorous tissues in these patients than that in normal liver tissue controls. Higher expression of MACC1
mRNA and nuclear protein in tumorous tissues in these patients was associated with shorter post cryoablation
median TTP and OS than that with lower MACC1 expression.
Conclusions: Cryoablation is a safe and effective therapeutic option for patients with advanced HCC and Child-pugh
class A or B cirrhosis; and a higher intratumoral expression of MACC1 or nuclear translocation predicts poor outcomes of
cryotherapy in these patients.
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Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the third most common cause of cancer-related
death worldwide [1]. Patients with advanced HCC carry
poor outcomes [2], and treatment has been limited [3,4]
until recent application of sorafenib that prolong survival
rates in a limited way in these patients [5,6]. Cryoablation
has been reported as a valid alternative to surgery for HCC
treatment in patients with cirrhosis [7]. The main advan-
tage of percutaneous cryotherapy over surgical resection is
that it can be used to selectively destroy HCC tumorous
tissue while sparing more non-tumoral liver tissue, and
therefore, better reserve liver function [8]. This is particu-
larly important to HCC, because the majority of these
patients have cirrhosis and compromised liver function.
Recently, Osada et al. and our group found that cryothe-
rapy causes not only local tumor necrosis, but also the ad-
jacent tumor tissue was necrotic and shrunken in HCC
patients following cryoablation, which is considered as ec-
topic tumor suppression [9,10]. Cryotherapy might also
improve host’s immunity following the treatment. We have
recently reported that the frequency of regulatory T cells
had significantly decreased in patients with HCC regres-
sion following cryoablation, but dramatically increased in
patients with HCC recurrence [11]. These indicated that
besides HCC ablation, cryotherapy might also function as a
systemic treatment by improved immunity. Although
cryoablation has not been widely accepted for treatment of
advanced HCC, studies reported this modality could pro-
long survival in patients with advanced HCC [12]. Al-
though a large volume of literature on cryotherapy results
in cryo-immunology response [11,13], there are many un-
answered questions regarding the role of cryoablation in
HCC treatment. Although cryoablation has been reported
to prolong survival in unresectable advanced HCC, the
sample size was too small to draw a reliable conclusion
[12]. Thus, randomized controlled studies are needed to
compare cryoablation with other therapies, such as resec-
tion and Radiofrequency Ablation (RFA).
Metastasis-associated in colon cancer-1(MACC1), a new
gene associated with primary and metastatic colon cancer,
promotes tumor cell growth as well as the development of
distant metastasis [14]. Overexpression of MACC1 induces
down-stream activation of HGF/c-Met and promotes me-
tastasis of colon cancer, while silencing of MACC1 leads to
reduced tumor proliferation, decreased cell migration, and
a lack of new metastasis [15,16]. Our recent studies found
that overexpression of MACC1 predicts a poor outcome in
patients with HCC after hepatectomy [17]. Together with
other reports [18], these findings imply that MACC1 might
serve as a novel prognostic marker in HCC. Thus, we
assessed whether intratumoral MACC1 is overexpressed
and associated with clinical outcomes in advanced HCC
after cryoablation.In the present study, we prospectively followed
patients who had undergone cryoablation for unresectable
Barcelona Clinic Liver Cancer (BCLC) stage C HBV-
related HCC in a relatively large clinical cohort of patients
than earlier studies. The main purpose of this study was to
evaluate the safety and effects of percutaneous cryoablation
for advanced HCC. We also assessed the distribution of
MACC1 expression and value of predicting the post
cryoablation outcomes in these patients.
Methods
Study concept
The study protocol was approved by the 302nd Hospital
Research Ethics Committee, and written informed con-
sent was obtained from all participants. The patients
undergoing cryoablation therapy and qualified the inclu-
sion criteria below at two tertiary medical centers from
February 2008 and August 2010 were prospectively
followed. The primary endpoint of the study was to de-
termine the time to progression (TTP) after cryoablation.
The secondary endpoints included overall survival (OS),
the disease-control rate (DCR) and safety of cryoablation.
The association of MACC1 mRNA and protein expres-
sion with post-cryoablation OS and TTP was also
assessed in the same cohort of patients.
Patients
A total of 120 patients with advanced HBV-related HCC
who underwent cryoablation therapy and qualified the
following inclusion criteria were selected from 378 con-
secutive patients and followed in Beijing the 302nd Hospital,
China. The inclusion criteria were: (A) diagnosis of HCC by
histologic confirmation and stage of unresectable BCLC
staging C with portal vein thrombosis(PVT), as a sign of
macroscopic vascular invasion [4]; (B) at least one tumor
lesion that could be measured along one dimension
according to the Response Evaluation Criteria in Solid
Tumors (RECIST) v1.1 criteria [19]; (C) presence of portal
hypertension and Child class A or B cirrhosis by endos-
copy, imaging, and clinical presentation with life expect-
ancy of at least 12 weeks [20]; (D) Eastern Cooperative
Oncology Group Performance Status (ECOG PS) of 0, 1
or 2; (E) total bilirubin ≤ 51.3 μmol/L; (F) HBsAg positive
and anti-HCV-negative; and (G) regular and minimal
3 months of follow-up prior to and post cryoablation.
None of the patients had received any prior HCC treat-
ment. Histological grade of HCC differentiation was
classified by Edmondson criteria into well, intermedi-
ate, and poorly differentiated [21].
A total of 258 patients were excluded, including 51
patients were Child-Pugh C; 44 patients with Child-Pugh
B, but serum bilirubin level >51.3 μmol/L; 25 patients with
life expectancy < 12 weeks; 13 patients with ECOG PS ≥ 3
and 69 patients with a history of prior HCC treatment
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TACE or local ablation = 45, radiotherapy = 8); 36 patients
extrahepatic spread; and 20 patients missed follow-up in
3 months after cryoablation.
HCC tumorous samples were obtained from all enrolled
120 patients at the time of cryoablation, and prepared for
histochemical staining or snap-frozen in liquid nitrogen for
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR). Microdissection was not per-
formed in current study. Part of the tissue specimens were
fixed in 10% formalin and paraffin-embedded for hema-
toxylin and eosin (H&E) and immunohistochemical stai-
ning (IHS). Because nontumoral tissue was not routinely
collected during diagnostic biopsy, ten normal liver tissues
were obtained as controls, including 4 from cases with he-
patic hemangioma and 6 with hepatic cyst. None of these
had history of viral hepatitis or cirrhosis.
Cryoablation procedure
Cryoablation was performed as previously described [22].
Briefly, the cryoablation procedure was performed under
conscious sedation. Echocardiography, ventilation and oxy-
gen saturation levels were monitored throughout the pro-
cedure. Patients were kept warm during cryoablation with
warming mats.
Argon-helium gas-based CRYO care system (EndoCare,
Inc., CA, USA) and cryoprobes (2 or 3 mm) were used to
freeze the tumor with a dual freeze-thaw cycle under
ultrasound or computerized tomography (CT)-guidance.
The cryoprobe temperatures were reduced to −135 ± 2°C
within 1 min. The dual freeze-thaw cycle comprised a
20-min freeze, a 10-min thaw and a further 15-min
freeze. After removal of the probes, all tracts were packed
with Surgicel (Johnson & Johnson, Inc., Arlington, TX,
USA) through the sheath introducer to control bleeding,
and the sheath introducer was removed. The size and
number of cryoprobes were determined depending on the
location and the average size of the HCC lesions to be
ablated. To maximally ablate tumor lesions, cryoablation
was performed once or up to a total of 3 sessions as
needed. To our experience, tumors less than 5 cm in diam-
eter can be completely ablated and tumors larger than
5 cm can be reduced by at least 70%.
Assessment of the clinical outcomes
Cryoablation treatment response
This was assessed by CT scan or magnetic resonance
imaging (MRI) approximately every 8 weeks via inde-
pendent radiologists and classified according to RECIST
v.1.1 assessment [19], i.e., complete response (CR), par-
tial response (PR), stable disease (SD), or progressive dis-
ease (PD). Patients who achieved CR, PR or SD were
defined as achieving clinical benefits (CB). Patients who
showed CR or PR were defined as achieving a clinicalefficacy response (CER), whereas disease control rate
(DCR) is defined as the total rate of CR, PR and SD.
Assessment of OS and TTP after cryoablation treatment
The OS was defined as the time from cryoablation initi-
ation to the date of death or the patient’s last follow-up
[23]. TTP was defined as the time from cryoablation ini-
tiation to the date of disease progression or death. The
disease progression was defined as the tumor progression
according to RECIST v.1.1 or progression of cirrhosis.
Safety assessment of cryoablation treatment
After the treatment, all patients were observed in an inten-
sive care unit overnight to monitor for life-threatening
delayed hemorrhage and other complications, such as
cryoshock syndrome (chills, fever, tachycardia, tachypnea
and temporary renal damage), liver abscess, intestinal fis-
tulas, fever, myoglobinuria, pulmonary edema, pneumo-
thorax, thrombocytopenia, pain, and skin frostbite. Follow
up postoperative management [24].
MACC1 mRNA expression with post-cryoablation OS and
TTP
Quantitation of MACC1 mRNA by RT PCR
The MACC1 mRNAs were quantified by standard re-
verse transcription polymerase chain reaction (RT-PCR)
[14,17] assay blindly to the clinical records. The follo-
wing PCR primers were used for MACC1 cDNA (136 bp),
50-TTCTTTTGATTCCTCCGGTGA-30(F) and 5’-ACTC
TGATGGGCATGTGCTG-3’(R). Briely, total RNA was
isolated from the tissues by using an RNA isolation kit
(Qiagene, Germany). The extracted RNA was quantified by
spectrophotometric measurement at A260, and the purity
was verified by the A260/A280 ratio >1.8. A total of 2 μg
RNA was used for the production of cDNA by reverse
transcriptase-PCR (SYBR PrimeScript RT-PCR Kit with
SYBR Premix Ex Taq; Takara, Japan). The cDNA templates
were subjected to PCR amplification under the following
conditions: pre-denaturation at 95° for 30 sec; 28 cycles of
denaturation at 95° for 5 s, annealing at 60° for 30 s
and extension at 72° for 30 s; and final extension at
72° for 10 min. The final products were analysed by
2.0% agarose gel electrophoresis and stained with ethi-
dium bromide. Each PCR was performed in triplicates.
The threshold cycle (Ct) value for triplicate reactions
was averaged, and the relative genomic expression was
calculated by 2-ΔCt value [ΔCt = Ct (MACC1) - Ct
(β-actin)] [25].
To assure the assay was not contaminated by trace
amount of DNA, PCR reactions were also performed in
RNA control samples that lacked reverse transcriptase
during cDNA synthesis. Each PCR was performed in
triplicate. β-actin mRNA (125 bp) measurement was
used as an internal control with the following primers:
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CTCGTAGCTCTTCT-30 (R).
Assessment of MACC1 in HCC tumorous and normal control
liver tissue by IHS
Paraffin-embedded HCC tumorous and additional 10 nor-
mal control liver tissue from patients with history of hep-
atic hemangioma (n = 4) or hepatic cyst (n = 6) were used
for MACC1 indirect immunohistochemical staining. Poly-
clonal rabbit anti-human antibody against MACC1 (1:50;
Sigma,St. Louis, USA) was used as primary antibody,
peroxidase-conjugated anti-mouse/rabbit immuoglobulin
(polymer Detection system, GBI, Mukilteo, USA) as the
secondary antibody, followed by 3-amino-9-ethylcarbozole
(AEC; GBI, Mukilteo, USA). For the negative control, PBS
was used to replace the first antibody that resulted in a
negative staining.
The MACC1 staining results were evaluated and cha-
racterized by two independent pathologists. The amount of
positive MACC1 staining, shown in red, was scored as pre-
viously reported [26]: 0, ≤10%; 1, >10–25%; 2, >25–50%;
3, >50–75%; and 4, >75%. The intensity of the special
staining was scored as follows: 0, negative; 1+, weak; 2+,
moderate; and 3+, strong. The final score was obtained by
multiplying the extent scores and intensity scores, which
produced values in a range from 0 to 12. A score of 0–4
was defined as a negative MACC1 expression (−); a score
of 6–8, an intermediate positive MACC1 (+); a score
of 9–12, a strong positive MACC1 (++).
Cell lines
Human hepatoma cell lines (HepG2, MHCC-97H,
MHCC-97 L) and the immortal nontumourigenic nor-
mal human hepatocyte cell line(L-02) were used to
screen the expression of MACC1 and c-Met. HepG2 was
purchased from the American Type Culture Collection
(Manassas, VA). L-02, MHCC-97H and MHCC-97 L were
obtained from the Type Culture Collection of the Chinese
Academy of Sciences (Shanghai, China) and maintained
under recommended culture conditions. Cells were grown
at 37°C in a humidified incubator containing 5% CO2 and
spread onto 6-well chamber slides for mRNA, western blot
analysis and cell transfection. PCR primers for c-Met
mRNA detection were also as described in our previous re-
port [17]. Protein extraction, immunoblot analysis for
MACC1 and c-Met were performed by Western blotting
as descibed [13]. Antibody against c-Met(diluted 1:1000)
and MACC1(diluted 1:800) were used as primary antibody.
β-actin-specific antibody served as loading controls(diluted
1:2000; sigma Chemical Co., USA ).
SiRNA Transfection, apoptosis and cell cycle analysis
Two pairs of sequences of small interfering RNA (siRNA)
targeting MACC1 called MACC1-siRNA1, MACC1-siRNA2 and negative control (si-Control) were designed
and synthesized by Guangzhou Borui Bioengineering
(Guangzhou, China) and their sequences are as follows:
MACC1-siRNA1: 50-CAA GGA AGU UUC UGU AUG
ATT-30, MACC1-siRNA2: 50-GAA AUA ACA GGA
AGA GAA ATT-30. Transfection of siRNA into MHCC-
97H and MHCC-97 L was carried out using Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA) and Opti-MEM
(Invitrogen, Carlsbad, CA), according to the manufac-
turer’s protocol. Transfection efficiency was monitored by
pEGFP-N1 plasmid (clontech), with 60%-70% efficiency.
Cells were harvested 48 h after siRNA transfection for
mRNA, protein, apoptosis and cell cycle analysis. Cells
were stained with Annexin V using cell Apoptosis Detec-
tion Kit for cell apoptosis analysis, or treated with PI
staining solution (0.03% Triton X-100, 5 mg/ml Rnase A
and 10 ug/ml propidium iodide) to determine cell cycle
status on a flow cytometer. The results are representative
of three independent experiments with triplicate samples
for each condition.
Statistical analysis
All statistical analysis was performed with SPSS version
16.0 software. Continuous data were expressed as me-
dian and range. A comparison between the groups was
performed using the χ2 test. Survival rates were
estimated by the Kaplan-Meier method and compared
by the log rank test. The Cox proportional hazards
model was used to determine the independent factors
on survival, based on the variables selected in univariate
analysis. P < 0.05 was considered statistically significant.
Results
Patient characteristics and clinical outcomes
Baseline characteristics are presented in Table 1. A
total of 285 cryoablations were performed in 193
tumors in 120 patients with unresectable HBV-related
advanced HCC, with 1, 2 and 3 procedures in 17, 41
and 62 patients, respectively. The median follow-up
was 9 months (range 3–18 months) and the median
OS and TTP for the whole cohort were 10.5 months
(95% confidence interval [CI] 9.0–12.0 months) and
5.5 months (95% CI: 4.3 –6.7 months), respectively
(Figure 1). Regarding the analysis for best response, 5
of 120 (4.2%) patients in cryotherapy exhibited CR
(Figure 1A), 15 (12.5%) patients achieved PR, and 55
(45.8%) patients achieved SD lasting >8 weeks. Fur-
thermore, 92 (76.7%) patients who died, 28 (30.4%)
were due to esophagogastric varices bleeding; 16
(17.4%), refractory ascites-induced renal failure; 14
(15.2%), liver failure; 24 (26.1%), recurrence/metastasis;
and 10 (10.8%), tumor rupture/hemorrhage. Overall, 58/92
(63%) died of cirrhosis related complication; and 34/92
(37%) died of HCC related complications.



























AFP(ng/ml), median (range) 1368 (7–20000)
ECOG: Eastern Cooperative Oncology Group;
HBV: hepatitis B virus; AFP: alfa-fetoprotein.
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Cryoablation procedure-related adverse events
Major complications occurred in 8 (6.7%) patients. Four
(3.3%) cases developed hepatorrhexis bleeding into the peri-
toneal cavity diagnosed 3–6 hours after the cryoablation
procedure, and all were successfully managed by immediate
transcatheter arterial embolization (TAE) and supportive
measures. Cryoshock syndrome occurred in 3 (2.5%) cases
with larger tumor load (i.e., a mean total estimated area of
HCC > 50–60 cm2). All these 3 patients recovered following
intravenous atropine and 5% sodium bicarbonate, covering
with an electric blanket, and oxygen inhalation. One patient
developed a liver abscess at the ablation zone that was not
absorbed, and the abscess content exuded from a scar of
the probe tract 1 month after cryoablation, and required
drainage.
Other post cryoablation complications included
fever (52/120, 43.3%), pain (47/120, 39.2%), skin frostbite
(41/120, 34.2%), right pleural effusion (39/120,32.5%),thrombocytopenia (31/120, 25.8% included 2 patients with
platelet count decreased more than 50% from pretreat-
ment, 29 patients with mildly decreased platelet from base-
line, which returned to the baseline for about 1 week after
cryoablation), pneumothorax (4/120, 3.3%), myoglobinuria
(3/120, 2.5%), and 2 patients (1.6%) developed stress-
related gastric mucosal lesion-induced hemorrhage and
they were treated with acid-inhibiting and gastric mucosa-
protecting agents.
Worsening liver function status
Percutaneous cryoablation caused transient and mild eleva-
tion in alanine aminotransferase (< 5 × ULN, 94/120,
78.3%) and total bilirubin (< 2 × ULN, 21/120, 17.5%)
levels. All these returned to baseline levels about 2 weeks
after cryoablation therapy (P > 0.05). However, hepatic de-
compensation or liver failure occurred in 5 (4.2%) patients
with Child-Pugh class B (score = 8) and trunk PVT, includ-
ing 3 developed new onset or worsening ascites, and 2
developed liver failure. Three of these 5 patients recovered
to baseline and two died of liver failure.
Association of intratumoral MACC1 expression with
clinical presentation and cryoablation therapy-related
outcomes
MACC1 mRNA expression
By quantitative RT-PCR assay, the level of intratumoral
MACC1 mRNA expression in these advanced HCC
patients (0.009 ± 0.005) was about 15-fold higher than
that in 10 normal control liver tissue (0.0006 ± 0.00005,
p = 0.0031, Figure 2A and 2B). According to the median
value of intratumoral MACC1 mRNA expression (0.009,
range: 0.0051–0.0139), these 120 cases were divided into
2 groups: those with low intratumoral MACC1 expres-
sion (<0.009) and those with high intratumoral MACC1
expression (≥0.009). A higher expression of MACC1
mRNA was significantly associated with ages, tumor
size, portal vein trunk invasion, multinodular and poorly
tumor differentiation, but not with gender, lesion num-
ber, AFP level or Child-Pugh class (Table 2).
As shown in Table 3, the overall CER and DCR in
this cohort of patients with advanced HCC and
received cryoablation were 16.7% (20/120) and 62.5%
(75/120), respectively. Compared to those with low
intratumoral MACC1 mRNA expression, patients with
high intratumoral MACC1 expression had a low CER
and DCR (8.3% vs. 25.0%, p = 0.0275 for CER; 51.7%
vs. 73.3%, p = 0.0273 for DCR). Moreover, the advanced
HCC patients with MACC1 nuclear staining had a
poorly CER and DCR than those with MACC1 cyto-
plasmic staining (12.8% vs. 16.7%, p = 0.843 for CER;
43.6% vs. 68.8%, p = 0.0321 for DCR).
The median post cryoablation TTP was 4.0 (95% CI:
3.0- 5.0) months in the group with higher intratumoral
Figure 1 Efficacy of cryoablation therapy for advanced hepatocellular carcinoma. A: a complete response in a 50-year-old man survived for over
24 months after cryoablation. MRI scan showed a huge mass (M) at the dome of the left hepatic lobe (a: T2 weighted image; b: arterial phase). Long
black arrow(b)indicated portal vein thrombosis (c: portal phase) with histopathological confirmation of HCC embolus, and Edmondson classification of
intermediate differentiation. Ten months after two cryoablation therapies, 60% reduction was achieved from the baseline tumor burden, also associated
with the decrease of the non-treated adjacent tumor (d). Long white arrow indicated the treated tumor was necrotic (e). Short black arrow indicated
portal vein tumor thrombus was almost invisible after cryoablation (f). B: Kaplan-Meier survival curves are shown for 120 advanced patients treated with
cryotherapy and the median TTP for the whole cohort was 5.5 months (95% CI 4.2 –6.7 months). C: Kaplan-Meier estimates of median overall survival for
advanced patients treated with cryotherapy was 10.5 months (95% CI 9.0–12.0 months).
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than the median TTP of 8.5 (95% CI: 6.3- 10.7) months in
the group with lower intratumoral MACC1 mRNA expres-
sion (log-rank P < 0.001, Figure 2C). In addition, a signifi-
cantly shorter median post cryoablation OS (9.0 months;
95% CI: 7.7- 10.3 months) was seen in the group with
higher intratumoral MACC1 mRNA expression than that
(12.0 months; 95% CI: 7.8- 16.2 months) in the group withlower intratumoral MACC1 mRNA expression (log-rank
P = 0.019; Figure 2D). To further determine the associ-
ation of MACC1 mRNA expression with post cryoablation
outcomes, the Cox hazard model was used for multi-
variable analysis. As shown in Table 4, the multivariate
analysis confirmed that OS after cryoablation treatment
for treating advanced HCC were independently associa-
ted with ECOG PS and overexpression of intratumoral
Figure 2 Expression of MACC1 and the outcomes of advanced HCC after receiving cryoablation therapy. A: MACC1 mRNA expression
measured by RT-PCR in tumorous tissue from patients with advanced HCC (upper panel, T1-T6) vs. normal liver tissue from controls (upper panel,
N1 and N2), and the lower panel was β-actin as internal controls. B: Mean MACC1 mRNA expression in tumorous tissue from patients with
advanced HCC (right) vs. that in control (left) by real-time RT-PCR. C: Kaplan–Meier estimates of time to progression in patients with higher
MACC1 mRNA expression vs. those with lower MACC1 mRNA expression (p < 0.001). D: Kaplan–Meier estimates of overall survival time in patients
with higher MACC1 mRNA expression vs. those with lower MACC1 mRNA expression (p < 0.019).
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pression of intratumoral MACC1 mRNA.
MACC1 Protein expression
We then determined expression and distribution of
MACC1 protein by IHS in the same HCC tumorous tis-
sue versus normal liver tissue controls. Absent or weak
cytoplasmic MACC1 expression in the normal control
livers tissue was observed (Figure 3A-a). In contrast, the
HCC tumorous tissues revealed variable degrees of cyto-
plasm and/or nuclei MACC1 staining (nuclear MACC1
positive was defined as at least 10% of nuclei stained).Overall, 87/120 (72.5%) HCC specimens showed posi-
tive staining for MACC1, including 39 (44.8%) with
nuclear staining and 48 (55.2%) with predominant dif-
fuse cytoplasmic staining (Figure 3A). We found
MACC1 nuclear expression were associated with poor
HCC differentiation (p = 0.0185) and larger tumor size
(p = 0.0175). Compared to patients with MACC1 cyto-
plasmic staining, those with MACC1 nuclear staining
had significantly shorter mean post cryoablation TTP
[4.0(3.6- 4.4) months vs. 5.0 (4.2-5.8) months, log-
rank: P < 0.001] and OS: [8.0 (6.7- 9.2) months vs.
11.0 (8.1- 13.9) months, log-rank: P = 0.01].
Table 2 The associaition of MACC1 mRNA expression with the baseline clinical presentation in advanced HCC patients
Variables All cases (n = 120 ) MACC1 mRNA high expression
(total cases = 60) [n(%)]
MACC1 mRNA low expression
(total cases = 60) [n(%)]
P value
Gender
Male 106 52(87) 54(90) 0.7761
Age
≥ 48 years 60 25(42) 38(63) 0.0283
Tumor size
≥ 6 cm 60 37(62) 18(30) 0.0010
HCC thrombus
Portal trunk 49 32(53) 17(28) 0.0093
HCC number
Multinodular 53 32(53) 21(35) 0.0432
Differentiation
Well 20 8(13) 12(20) 0.0347
Moderately 50 20(34) 30(50)
Poorly 50 32(53) 18(30)
Serum AFP
≥1368 85 41(68) 44(73) 0.6879
HBV DNA
Positive 76 36(60) 40(67) 0.4486
Child-Pugh
A 58 31(52) 27(45) 0.4650
B 62 29(48) 33(55)
Yang et al. Journal of Translational Medicine 2013, 11:41 Page 8 of 14
http://www.translational-medicine.com/content/11/1/41MACC1 and c-Met expression associated with tumor cell
proliferation and apoptosis
We then examined MACC1 mRNA and protein expres-
sion in four liver cell lines by real-time quantitative PCR
and western blot. Data showed that there was a lack of
MACC1 expression in the normal liver cell line L-02,
while all of three hepatoma cell lines (HepG2, MHCC-
97L and MHCC-97H) expressed MACC1. MHCC-97L
and MHCC-97H showed higher MACC1 transcript
levels relative to the HepG2(p < 0.05, Figure 4A).
Likewise, MACC1 protein expression was elevated in
MHCC-97L and MHCC-97H compared to the HepG2Table 3 MACC1 expression and outcomes of post-cryoablatio
MACC1 mRNA expression




7.7-10.3 (M) 7.8-16.2 (M)
Overall response rate (CR + PR) 5(8.3%) 15(25.0%)
Disease control rate (CR + PR + SD) 31(51.7%) 44(73.3%)
Abbreviations: Overall response rate: includes complete and partial response. Disease co(p < 0.05, Figure 4B). As for c-Met, both of MHCC-97H
and MHCC-97L had higher level than that of L-02 or
HepG2 cells (p < 0.05, Figure 4A). After transfection of
siRNA targeting MACC1 to MHCC-97H and MHCC-97L
cells, which express high level of endogenous MACC1,
the MACC1 and c-Met mRNA levels and protein expres-
sion were significantly inhibited compared to the control
groups (P < 0.05, Figure 5A, 5B). We further investi-
gated if down-regulation of MACC1 expression was
associated with tumor cell apoptosis and cycle by
using flow cytometric analysis. Cell cycle analysis revealed
that MACC1 silencing in MHCC 97H and MHCC 97Ln therapy
P MACC1 protein localization P
Cytoplasmic (n = 48) Nuclear (n = 39)
< 0.001 5.0 4.0 <0.001
4.2-5.8 (M) 3.6-4.4 (M)
0.019 11.0 8.0 0.001
8.1-13.9(M) 6.7-9.2(M)
0.027 8(16.7%) 5(12.8%) 0.843
0.027 33(68.8%) 17(43.6%) 0.0321
ntrol rate: includes complete, partial response and stable disease. M: months.
Table 4 Multivariate analysis of prognosis factors
associated with post-cryoablation survival in 120 patients
with advanced HCC
Variables Multivariate
RR CI 95% P
Time to progression
Age 0.465 0.201-1.128 0.082
ECOG PS 1.428 1.014-1.823 0.221
Child-Pugh class 1.126 1.051-1.517 0.329
Tumor diameter 0.721 0.437-1.207 0.221
Tumor number 0.938 0.783-1.178 0.746
Tumor differentiation 1.246 0.752-1.972 0.384
MACC1 mRNA expression 2.103 1.378-2.801 0.005
HCC thrombus in PV 1.033 0.662-1.734 0.881
Overall survival
Age 0.569 0.301-1.216 0.278
ECOG PS 1.452 1.021-2.033 0.026
Child-Pugh class 1.127 1.038-1.861 0.105
Tumor diameter 1.221 0.332-1.325 0.763
Tumor number 0.873 0.661-1.148 0.332
Tumor differentiation 1.142 0.673-2.116 0.736
MACC1 1.842 1.201-2.514 0.011
HCC thrombus in PV 1.058 0.483-2.354 0.825
PV: portal vein.
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crease in the G0-G1 phase compared with control siRNA-
transfected cells(Figure 5C, p < 0.05). Cells transfected
with MACC1-siRNA1 and MACC1-siRNA2 showed sig-
nificantly increased apoptotic rates as compared to con-
trol siRNA-transfected cells (MHCC 97H: 20.1%, 16.9%
vs 6.95%, p < 0.05; MHCC 97L: 17.7%, 15.4% vs 5.46%,
p < 0.05) (Figure 5D). Above results indicate that expres-
sion of MACC1 are associated with tumor cell prolife-
ration and apoptosis.
Discussion
It is well known that the patients with advanced HCC
carry extremely poor outcomes [27]. These patients gen-
erally do not tolerate, nor response to systemic chemo-
therapy and local radiation therapy [28]. Thus, the
treatment options for these patients remain limited. Al-
though sorafenib may improve outcomes in these
patients [5,6], the patient tolerance is usually low, the
effects remain limited, and the cost could be high for
this option. Thus, developing new therapies to this
group of HCC patients is urgently needed. Cryoablation
has been shown to induce growth inhibition of un-
resectable tumor and offers several potent advantages
versus other ablation methods [29], but the data on
cryoablation for advanced HCC remains very limited.Wilson et al. reported that cryoablation was a promising
therapy for advanced HCC with potential benefits in
prolonging patient survival [8]. A recent cohort study
indicated that cryotherapy is safe and effective for
unresectable HCC or recurrent HCC [12].
In the present study, we prospectively analyzed 120
cases with BCLC stage C unresectable HCC, underwent
cryoablation, the largest sample size in this type of study
to our best knowledge. According to the historical stud-
ies with the compared of patient populations, despite
RFA provided the median OS of 8.5 months and TTP of
4.2 months in this type of patients, the reported after
RFA for unresectable advanced HCC have not got any a
case of CR [30]. Our data showed that cryoablation in
patients with BCLC stage C unresectable HCC resulted
in a significantly improved median post cryoablation OS
(10.5 months) and TTP (5.5 months) with CER and
DCR being 16.7% and 62.5%, respectively. Especially, five
(4.2%) of these patients showed growth inhibition of
non-treated tumor induced by post-cryoablation and
3 of them be alive up to the end of the follow-up
(Figure 1). Thus, our findings further indicated that be-
sides HCC ablation, cryotherapy might also function
as a systemic treatment by improved immunity, in-
dicated a comparable or even better OS and TTP, and
other survival segregates of cryoablation in patients with
advanced stage of HCC, compared to other current
standard therapies, such as percutaneous ethanol injec-
tion and RFA as historically reported [31,32]. In ad-
dition, cryoablation has several advantages as follow.
First, the cryoablation has the ability to produce larger
and more precise zones of ablation [33]. Second, the
frozen tissue is identified as a hyperechoic boundary
with dense posterior shadowing, which allows excel-
lent visualization of the nearest aspect of the ablation
zone can be carefully monitored by US or CT or MRI
[34,35]. Third, percutaneous cryoablation produce mild
related-pain without general anaesthesia [36]. Last, tu-
mour seeding after percutaneous cryoablation for HCC
is low [37-39]. Our data support further randomized
multicenter clinical trials to validate our findings.
Previous studies showed cryoablation was associated
with 11% major complications [40,41]. We found al-
though the majority was minor complications, severe
complications, such as hepatorrhexis bleeding and Cryo-
shock syndrome, occured in 6.7% patients. To our
experience [24], tumors with larger size, subcapsule loca-
tion without encompassed liver parenchyma or adjacent
to the gallbladder or loops of bowel will increase the risk
of severe complications. Inserting the cryoprobe across a
portion of normal hepatic parenchyma for subcapsular
tumours can in some degree minimise both liver haem-
orrhage and needle-tract seeding. Cryoablation could ef-
fectively spare the normal livers, but severe liver damage
Figure 3 Nuclear expression of MACC1 protein and overall survival after cryoablation therapy. A. The expression of MACC1 protein
detected by immunohistochemistry (×400). a. Normal control liver tissue showed a weak MACC1expression in cytoplasm. b. A HCC case showed
a mainly cytoplasmic MACC1 expression in tumor tissue (arrowhead). c. Another case with both weak cytoplasmic and sporadic nuclear MACC1
expression(arrowhead). d. The predominant nulear MACC1 expression in the tumorous tissue of a HCC patient (arrowhead). B. Kaplan–Meier estimates of
time to progression in patients with nuclear MACC1 expression vs. those with cytoplasmic MACC1 expression (p < 0.001). C: Kaplan–Meier estimates of
overall survival time in patients with nuclear MACC1 expression vs. those with cytoplasmic MACC1 expression (p < 0.01).
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function (Child-Pugh classification score >8) or after a
large area of ablation. We believe compromised liver
function and total estimated area (TEA) should be
considered to deliver the effective ablation of the tumors
and avoid severe complications in patients with advanced
HCC. In this corhort of patients, the 30-day post-
cryoablation mortality rate was 0%, suggesting that
cryoablation significantly improved clinical outcomes in
these patients with acceptable tolerance and safety
profiles as previously reported [8,40,41].Our findings provide a strong rationale for not only
further multicenter prospective studies to validate our
results, but also studies on combination therapy of
cryoablation with sorafenib. Indeed, our early single cen-
ter study did support the feasibility of this combination
therapy in HCC patients [42].
Although we demonstrated significant short-term
therapeutic benefits of cryoablation, 76.7% patients died
during post-cryoablation follow up. This is not surpris-
ing as these patients had Child class A-B cirrhosis,
advanced HCC and 40.8% had imaging report of the
Figure 4 The expression of MACC1 and c-Met mRNA and protein in liver cell lines. A: MACC1 and c-Met mRNA in three human hepatoma
cell lines (MHCC-97 L, MHCC-97H and HepG2) and one normal liver cell line, L-02, by real-time RT-PCR. (Δp < 0.05 versus HepG2, *p < 0.05 versus
L-02 or HepG2). B: MACC1 and c-Met protein expression in above cell lines, by western blot. (Δp < 0.05 versus HepG2, *p < 0.05 versus L-02
or HepG2).
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http://www.translational-medicine.com/content/11/1/41main PVT. Most common etiology of mortality was vari-
ceal bleeding, likely due to severe portal hypertension
secondary to portal vein thrombosis. Majority (63%) died
of cirrhosis related complications and 37% died of HCC
related complication, as previously reported [43].
MACC1 is a recently identified molecule involved in
metastasis of colon cancers [14]. Previous studies on the
association of MACC1 with HCC were largely focused
on BCLC stage A, but not stage C HCC [17,18]. The
present study included a uniform group of BCLC stage
C HCC, providing a great opportunity to assess this
issue. We found that those with a lower intratumoral
MACC1 mRNA expression had significant higher CER
(p = 0.027) and CDR (p = 0.023) than those with a higher
intratumoral MACC1 mRNA expression. Consistent
with these, those with a lower intratumoral MACC1
mRNA expression showed significantly longer median
post cryoablation TTP and OS than those with a higher
intratumoral mRNA MACC1 expression. Because overex-
pression of MACC1 induces down-stream activation of
HGF/c-Met and promotes tumor cell growth as well as
tumor cell invasion [15], clinically we found a higher
intratumoral MACC1 mRNA level was significantly more
associated with younger age, portal vessel trunk invasion,
tumor size, tumor number and poorly tumor differenti-
ation. Our data extended the previous findings [17,18] and
suggested that intratumoral MACC1 mRNA expression
might serve as a clinical surrogate for clinical presenta-
tion and post cryoablation outcomes in patients with
HBV-related cirrhosis and BCLC stage C HCC.
Besides MACC1 mRNA expression, we also found that
nuclear MACC1 protein overexpression was presented in
44.8% of tumorous samples from these patients with
advanced HCC. Furthermore, nuclear MACC1 expression
at the time of cryoablation was not only strongly associatedwith larger tumor size and poorly differentiation, but also
associated with poor outcome in these patients. Those with
nuclear MACC1 staining had shorter median TTP and OS
than those with MACC1 cytoplasmic staining. These
findings are consistent with that reported in primary colon
cancers [14], and our recent report that MACC1 mRNA
overexpression is associated with enhanced tumor progres-
sion and may serve as a surrogate to predict recurrence or
metastasis after hepatectomy [17]. Although the precise
underlying mechanism remains to be determined, in vitro
we found that the HCC cell lines with highly metastasis
potential, especially MHCC-97H and MHCC-97 L [44],
had a relatively high MACC1 and c-Met expression,
whereas suppressing of MACC1 by si-RNA significantly
reduced c-Met expression. Our data further confirmed that
silencing of MACC1 resulted in c-Met suppressed expres-
sion, cell cycle arrest and apoptosis induction. These
results shed new insights into the molecular mechanisms
involved in the progression and prognosis of HCC, it
seems that the nuclear translocation of MACC1 may be
associated with c-Met and co-contribute to the pathogen-
esis of HCC [18,45] and affect outcomes of advanced
HCC. Distribution of MACC1 expression in HCC cells
may help us to select the best appropriate patients for
cryotherapy, since the absence of therapeutic alternatives
for advanced HCC.
Multivariable analysis showed that high intratumoral
MACC1 mRNA expression, together with ECOG PS,
predict the outcomes of post-cryoablation treatment in
patients with unresectable and BCLC stage C HCC. It
should be noted that besides MACC1 overexpression, we
also found that ECOG PS was independently associated
with OS, which was consistent with the results of previ-
ous studies [46]. Ideally, the tumor control rate increases
with the completion of local treatment. Patients with a
Figure 5 MACC1 and c-Met expression associated with tumor cell cycle and apoptosis. A. Comparison of MACC1 and c-Met mRNA levels
in MHCC-97H and MHCC-97 L cell lines transfected with two pairs of MACC1-si RNA and control-si RNA, as determined by real-time RT-PCR (Δp < 0.05
versus blank or si-control, *p < 0.05 versus blank or si-control). B. MACC1 and c-Met protein expression in MHCC-97H and MHCC-97 L cell lines
transfected with two pairs of MACC1-si RNA and control-si RNA, as determined by Western Blot. C: The cell cycle analysis in MHCC-97H and MHCC-97
L cell lines transfected with MACC1-siRNA by Flow cytometric analysis. D: The percentage of apoptotic cells in MHCC-97H and MHCC-97 L cell lines
transfected with MACC1-si RNA by Flow cytometric analysis.
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http://www.translational-medicine.com/content/11/1/41better ECOG PS had the opportunity for successful local
treatment because of acceptable adverse effects. How-
ever, some well-established prognostic predictors, such
as tumor differentiation, HCC tumor size and alpha-
fetoprotein level were not found to be associated with
post cryoablation outcomes in the present study. PVT is
generally accepted to be the most independent factors
affecting survival in HCC patients [47], but the sub-
location of thrombus, whether in branch or trunk portal
vein, was also excluded from multivariable analysis. Be-
cause the HCC patients in previous studies included dif-
ferent staging, the baseline PVT was a significant
predictor for worse survival in HCC patients [48].
Considering that all of patients have PVT in current
study, it was as one of the inclusion criteria and an iden-
tical factor that may contribute to the prognosis between
patients with high or low MACC1 expression. Hence,
PVT was excluded from multivariate analysis.
Conclusions
The present study demonstrated that cryoablation is a
safe and effective therapy for BCLC stage C unresectable
HCC with Child class A or B. MACC1 mRNA and pro-
tein nuclear overexpression was associated with clinical
presentation of more advanced HCC and poor outcomes
after cryoablation. It should be noted, this was an uncon-
trolled, prospective followed study, further randomized
and control studies are needed to validate our findings.
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